DGI
OMED

Disciplined Growth Investors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Disciplined Growth Investors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-151,879
Closed -$351K – 90
2018
Q2 		$351K Sell
151,879
-157,338
-51% -$458K 0.01% 83
2018
Q1 		$983K Sell
309,217
-5,248
-2% -$14.5K 0.02% 83
2017
Q4 		$1.29M Buy
314,465
+690
+0.2% +$3K 0.03% 84
2017
Q3 		$1.42M Sell
313,775
-15,325
-5% -$62.1K 0.03% 83
2017
Q2 		$1.1M Buy
329,100
+4,750
+1% +$19.7K 0.02% 83
2017
Q1 		$2.99M Sell
324,350
-2,550
-0.8% -$22.4K 0.07% 84
2016
Q4 		$2.52M Buy
326,900
+25,975
+9% +$239K 0.06% 84
2016
Q3 		$3.44M Sell
300,925
-4,700
-2% -$54.7K 0.08% 79
2016
Q2 		$3.76M Sell
305,625
-3,325
-1% -$40.3K 0.09% 79
2016
Q1 		$3.12M Buy
308,950
+350
+0.1% +$4.11K 0.08% 82
2015
Q4 		$6.96M Sell
308,600
-1,550
-0.5% -$31.8K 0.18% 64
2015
Q3 		$5.14M Buy
+310,150
New +$6.22M 0.13% 70

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Disciplined Growth Investors's OMED Position: Q3 2018 in Review

Disciplined Growth Investors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 151,879 shares — an estimated $351K sold.

Disciplined Growth Investors first reported a position in OMED in Q3 2015 and held it in 12 quarters. The position peaked at $6.96M in Q4 2015. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

  • Disciplined Growth Investors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Disciplined Growth Investors sold 151,879 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $351K.
  • Disciplined Growth Investors first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2015 and held it in 12 quarters.
  • Disciplined Growth Investors's OncoMed Pharmaceuticals, Inc. position peaked at $6.96M in Q4 2015.
  • 54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on Disciplined Growth Investors's 13F filing for Q3 2018, filed 16 Nov 2018.